Business Analysts Set Adaptive Biotechnologies Price Target at $13.22 Adaptive Biotechnologies Corporation (NASDAQ: ADPT) has received a consensus rating of “Moderate Buy” from ten analysts, according to MarketBeat.com. This rating reflects a mix... Editorial3 hours ago